Tezepelumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tezepelumab" in English language version.

refsWebsite

Global rank English rank

12web.archive.org

1^st place

6nih.gov

4^th place

4doi.org

2^nd place

3astrazeneca.com

low place

3semanticscholar.org

11^th place

8^th place

3europa.eu

68^th place

117^th place

2fda.gov

447^th place

338^th place

1harvard.edu

18^th place

17^th place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1hpfb-dgpsa.ca

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

astrazeneca.com

"Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
"Tezepelumab granted Breakthrough Therapy Designation by US FDA". AstraZeneca (Press release). 7 September 2018. Archived from the original on 10 September 2018. Retrieved 10 September 2018.
"Tezspire approved in the EU for the treatment of severe asthma" (Press release). AstraZeneca. 21 September 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022.

canada.ca

health-products.canada.ca

"Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.

clinicaltrials.gov

"Studies found for: Tezepelumab". ClinicalTrials.Gov. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services. Archived from the original on 30 July 2022. Retrieved 14 March 2020.

doi.org

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891. S2CID 202746054.
Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. 80 (5): 449–458. doi:10.1007/s40265-020-01273-4. PMID 32078149. S2CID 211194472.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. (May 2021). "Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma". New England Journal of Medicine. 384 (19): 1800–09. doi:10.1056/NEJMoa2034975. PMID 33979488. S2CID 234484931.

europa.eu

ema.europa.eu

"Tezspire EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tezspire: Pending EC decision". European Medicines Agency. 21 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Tezspire Product information". Union Register of medicinal products. 12 December 2022. Archived from the original on 27 October 2022. Retrieved 3 March 2023.

fda.gov

"Drug Trials Snapshots: Tezspire". U.S. Food and Drug Administration (FDA). 17 December 2021. Archived from the original on 28 July 2023. Retrieved 28 July 2023. This article incorporates text from this source, which is in the public domain.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

harvard.edu

ui.adsabs.harvard.edu

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Tezspire". Health Canada. 19 October 2022. Retrieved 3 March 2024.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Tezspire". Health Canada. 23 October 2014. Archived from the original on 24 January 2023. Retrieved 24 January 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891. S2CID 202746054.
Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. 80 (5): 449–458. doi:10.1007/s40265-020-01273-4. PMID 32078149. S2CID 211194472.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. (May 2021). "Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma". New England Journal of Medicine. 384 (19): 1800–09. doi:10.1056/NEJMoa2034975. PMID 33979488. S2CID 234484931.

ncbi.nlm.nih.gov

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.

dailymed.nlm.nih.gov

"Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.

semanticscholar.org

api.semanticscholar.org

Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891. S2CID 202746054.
Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. 80 (5): 449–458. doi:10.1007/s40265-020-01273-4. PMID 32078149. S2CID 211194472.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. (May 2021). "Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma". New England Journal of Medicine. 384 (19): 1800–09. doi:10.1056/NEJMoa2034975. PMID 33979488. S2CID 234484931.

web.archive.org

"Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
"Summary Basis of Decision - Tezspire". Health Canada. 23 October 2014. Archived from the original on 24 January 2023. Retrieved 24 January 2023.
"Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
"Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
"Tezspire EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tezepelumab granted Breakthrough Therapy Designation by US FDA". AstraZeneca (Press release). 7 September 2018. Archived from the original on 10 September 2018. Retrieved 10 September 2018.
"Drug Trials Snapshots: Tezspire". U.S. Food and Drug Administration (FDA). 17 December 2021. Archived from the original on 28 July 2023. Retrieved 28 July 2023. This article incorporates text from this source, which is in the public domain.
"Tezspire approved in the EU for the treatment of severe asthma" (Press release). AstraZeneca. 21 September 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"Tezspire: Pending EC decision". European Medicines Agency. 21 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tezspire Product information". Union Register of medicinal products. 12 December 2022. Archived from the original on 27 October 2022. Retrieved 3 March 2023.
"Studies found for: Tezepelumab". ClinicalTrials.Gov. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services. Archived from the original on 30 July 2022. Retrieved 14 March 2020.